Intriguingly, RET fusions also develop as a mechanism of acquired resistance to EGFR inhibitor treatment in NSCLC (Piotrowska et al. 2018, Wang et al. 2022). This evidence concerns the gene EGFR and non-small cell lung carcinoma.